Predicción de sensibilidad a la warfarina basada en VKORC1 y CYP2C9 en pacientes de diferentes lugares de Colombia

Introduction: Seeking to prevent hemorrhages associated with anticoagulant therapy, a major goal is to validate predictors of sensitivity to warfarin. However, previous studies in Colombia that included polymorphisms in the VKORC1 and CYP2C9 genes as predictors reported algorithms with different performance to explain the dose variation and did not evaluate the prediction of sensitivity to warfarin. Objective: To determine the accuracy of the pharmacogenetic analysis that includes the polymorphisms: CYP2C9 *2 and *3 and VKORC1 1639G>A, for predicting sensitivity to warfarin in patients of the Central Military Hospital, a reference center of patients born in different places in Colombia. Materials and methods: Demographic and clinical data were obtained from 130 patients with stable dose of warfarin for more than 2 months. Next, their genotypes were obtained through a melting curve analysis. After verifying the Hardy-Weinberg equilibrium of the genotypes from the polymorphisms, it was done a statistical analysis, which included multivariate and predictive approaches. Results: It was built a pharmacogenetic model that explained the 52.8% of dose variation (p A (p<0.001). Conclusions: These results in a mixed population support the prediction of sensitivity to Warfarin based on polymorphisms in VKORC1 and CYP2C9 , as a valid approach in Colombian patients.